Kingsview Wealth Management Trims Gilead Sciences Stake

Institutional investor reduces holdings in biopharmaceutical company by 60.1% in Q3

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

Kingsview Wealth Management LLC cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 60.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,513 shares of the biopharmaceutical company's stock after selling 24,866 shares during the period.

Why it matters

Gilead Sciences is a major player in the biopharmaceutical industry, particularly in the areas of antiviral therapies for HIV and viral hepatitis. Changes in institutional ownership of the company's stock can provide insights into market sentiment and investment trends.

The details

According to the 13F filing, Kingsview Wealth Management reduced its holdings in Gilead Sciences from 41,379 shares to 16,513 shares during the third quarter of 2026. The firm's position in Gilead was valued at $1.83 million at the end of the quarter.

  • Kingsview Wealth Management filed the 13F report for the 3rd quarter of 2026.

The players

Kingsview Wealth Management LLC

An institutional investor that manages a portfolio of investments, including shares in Gilead Sciences.

Gilead Sciences, Inc.

A biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need, particularly antiviral therapies for HIV and viral hepatitis.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Kingsview Wealth Management's Gilead Sciences holdings could signal a shift in investor sentiment towards the biopharmaceutical company, though further analysis of broader market trends and the company's performance would be needed to draw any definitive conclusions.